TMB-H + EGFR exon 19 deletion
|
LUAD
|
TMB-H + EGFR exon 19 deletion
|
LUAD
|
EGFR inhibitor Resistant: C3 – Early Trials
|
EGFR inhibitor Resistant: C3 – Early Trials
|
TMB-H + EGFR exon 19 deletion
|
NSCLC
|
TMB-H + EGFR exon 19 deletion
|
NSCLC
|
osimertinib Resistant: C3 – Early Trials
|
osimertinib Resistant: C3 – Early Trials
|